0.01 % atropine - eye drops for prevention myopia progression in children and adolescents: First experiences - Myopia development up to one year

Poster Details

First Author: A.Fricke GERMANY

Co Author(s):    Y. Dieks   F. Kretz   G. Auffarth   D. Breyer   K. Klabe   H. Kaymak              

Abstract Details


Since 2014, atropine eye drops have been a potential treatment option against myopic progression in children. It was found that daily-low dose drops (0.01% atropine) significantly inhibits myopia development. Therefore, a preventive treatment with atropine is recommended, especially in the East Asian region, for schoolchildren with a myopia progression of -0.75 D per year. In the present study the course of the myopia progression and the compliance of the patients with the atropine eye dropper therapy used in our practice will be investigated.


Internationale Innovative Ophthalmochirurgie Düsseldorf, Germany; International Vision Correction Research Network, Germany


In 28 children and adolescents between the ages of 5 and 14 were treated with atropine eye drops, the development of myopia was observed over a period of up to one year. Our treatment consists of an evening drop on Sunday, Tuesday and Thursday with 0.01% atropine solution, as well as the recommendation of a multi-hour stay outdoors. The measurements includes dynamic pupillometry, pupil diameter under photopic and mesopic conditions and the axial length (Aladdin; Topcon). Furthermore the accommodation (near point) was determined.


Myopia development has been significantly slowed in all observed children. Compared to a similar pretreatment period, the progression was halved in almost all cases. By means of dynamic pupillometry it could be shown that the pupil play before and after therapy is largely unchanged. The accommodation point moved about 2-6 cm. The drops were well tolerated by all children, only 2 children reported slight discomfort when dripping.


A very good compliance of the children (and the parents) has been achieved by the application of the low doses of atropine eye drops (only three times a week). The functional changes by 0.01% atropine solution are minimal. On average, a slight pupillary dilatation of a maximum of 1 mm is to be expected. Clinically relevant accommodation inhibition is rather excluded.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy